As predicted, Fah–/–; Hpd–/– mice show reduced risk of HCC compared to Fah–/– mice treated with NTBC; thus, bypassing this pathway via deletion of the HPD gene could be an effective treatment for HT-I patients [39]. Here, FAH is linked to hepatocellular carcinoma.